| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
57,080,000 |
| Market
Cap: |
196.93(M) |
| Last
Volume: |
97,895 |
Avg
Vol: |
97,622 |
| 52
Week Range: |
$1.32 - $4.2 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.5 |
| Insider 6 Months : 5.2 |
| Insider 3/6 Months : 9.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,500 |
4,000 |
5,598 |
32,898 |
| Total Buy Value |
$10,840 |
$11,733 |
$14,587 |
$57,671 |
| Total People Bought |
2 |
3 |
3 |
5 |
| Total Buy Transactions |
2 |
3 |
4 |
11 |
| Total Shares Sold |
25,000 |
25,000 |
25,000 |
45,000 |
| Total Sell Value |
$76,500 |
$76,500 |
$76,500 |
$118,240 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lewis Joel |
President and CEO |
• • – |
2023-05-15 |
4 |
A |
$1.64 |
$19,267 |
D/D |
11,748 |
871,894 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-04-28 |
4 |
A |
$1.76 |
$19,267 |
D/D |
10,947 |
860,146 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-04-14 |
4 |
A |
$2.01 |
$19,266 |
D/D |
9,585 |
849,199 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-03-15 |
4 |
A |
$1.90 |
$19,266 |
D/D |
10,140 |
830,439 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-03-01 |
4 |
D |
$2.07 |
$156,345 |
D/D |
(75,529) |
820,299 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-02-28 |
4 |
A |
$2.07 |
$19,268 |
D/D |
9,308 |
895,828 |
|
- |
|
| Eldred Kary |
|
• • – |
2023-02-21 |
4 |
B |
$1.59 |
$1,591 |
D/D |
1,000 |
47,215 |
0.01 |
-10% |
|
| Lewis Joel |
President and CEO |
• • – |
2023-02-16 |
4 |
B |
$1.52 |
$1,520 |
I/I |
1,000 |
1,000 |
0.01 |
-7% |
|
| Lewis Joel |
President and CEO |
• • – |
2023-02-15 |
4 |
A |
$1.44 |
$19,267 |
D/D |
13,380 |
886,520 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-02-07 |
4 |
A |
$1.43 |
$205,685 |
D/D |
143,836 |
873,140 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2023-01-31 |
4 |
A |
$1.16 |
$17,500 |
D/D |
15,086 |
729,304 |
|
- |
|
| Uihlein Richard E |
|
• • • |
2023-01-26 |
4 |
A |
$1.11 |
$40,000 |
D/D |
36,036 |
7,999,291 |
|
- |
|
| Eldred Kary |
|
• • – |
2023-01-25 |
4 |
B |
$1.11 |
$1,443 |
D/D |
1,300 |
46,215 |
0.01 |
40% |
|
| Lewis Joel |
President and CEO |
• • – |
2023-01-13 |
4 |
A |
$1.14 |
$17,500 |
D/D |
15,351 |
714,218 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-12-30 |
4 |
A |
$1.13 |
$17,500 |
D/D |
15,487 |
698,867 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-12-15 |
4 |
A |
$1.16 |
$17,500 |
D/D |
15,086 |
683,380 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-11-30 |
4 |
A |
$1.27 |
$17,501 |
D/D |
13,780 |
668,294 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• • – |
2022-11-17 |
4 |
B |
$1.32 |
$5,280 |
D/D |
4,000 |
7,614 |
0.01 |
54% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-11-15 |
4 |
A |
$1.24 |
$17,500 |
D/D |
14,113 |
654,514 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-10-31 |
4 |
A |
$1.38 |
$17,500 |
D/D |
12,681 |
640,401 |
|
- |
|
| Freeman Kevin D |
|
• • – |
2022-10-28 |
4 |
B |
$1.41 |
$14,100 |
I/I |
10,000 |
75,000 |
0.01 |
39% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-10-14 |
4 |
A |
$1.62 |
$17,499 |
D/D |
10,802 |
627,720 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-09-30 |
4 |
A |
$1.79 |
$19,217 |
D/D |
10,736 |
616,918 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-09-30 |
4/A |
A |
$1.63 |
$17,500 |
D/D |
10,736 |
616,918 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2022-09-15 |
4 |
A |
$1.79 |
$17,501 |
D/D |
9,777 |
606,182 |
|
- |
|
516 Records found
|
|
Page 2 of 21 |
|
|
0.05 (1.43%) 
